EASME

Vital Beats is a developer of a medical platform focused on providing clinical decision support for the remote care of heart patients with pacemakers. The platform employs machine learning and participatory design principles, combined with advanced analytics, to continuously monitor cardiac devices. By utilizing a patent-pending technique, it triages patients effectively, allowing for timely interventions. This approach enhances the management of chronic conditions, ensuring that patients benefit from digital healthcare solutions that monitor their implanted devices around the clock. Vital Beats emphasizes user experience by integrating Nordic aesthetics into its platform, making it both enjoyable and valuable for users.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Nuada is a company based in Braga, Portugal, specializing in the development of innovative systems that enhance hand function. Its products are designed to improve performance in healthcare, sports, and various professional activities. Nuada's solutions feature lightweight, breathable, and flexible smart textiles that can be customized to meet individual needs. The technology is non-intrusive and aims to be an essential everyday wearable, providing users with a seamless experience that they may even forget they are wearing.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Neuro Device Group S.A., founded in 2008 and based in Warsaw, Poland, specializes in the development and manufacturing of medical devices aimed at addressing neurological disorders. The company's key products include the Neuro Device Camri, a recording camera for diagnostics within MRI scanners; the Neuro Device Scent, which assesses human neuronal responses to scents; and the Neuro Device Tacti, a stimulator used for identifying brain sensory motor areas during preoperative fMRI diagnostics. In addition to its proprietary devices, the company distributes a range of neurological products from leading manufacturers in various fields, including eye tracking, rehabilitation, and virtual reality. Neuro Device Group is committed to enhancing neurological research and improving health outcomes through innovative technology.

Bioithas is a biotechnology company dedicated to medical research. Its primary focus is the development of natural treatments that target the root cause of health issues, rather than just symptoms. The company conducts clinical trials in humans to test and validate its personalized treatments, aiming to enhance users' quality of life and overall well-being.

TomoWave is a company focused on developing innovative imaging technologies for clinical medicine and preclinical research. Utilizing its proprietary optoacoustic and laser ultrasonic imaging modalities, TomoWave aims to enhance cancer detection, guide medical interventions, and monitor the effectiveness of cancer therapies. The company's technology, which captures images by "listening to the sound of light," allows for highly detailed visualization of tissues, particularly in relation to vascular and blood-related conditions. Founded by Dr. Alexander Oraevsky, a pioneer in biomedical optoacoustics, TomoWave has a strong emphasis on generating intellectual property and advancing it from concept to validated clinical prototypes. The company is committed to bringing its technologies to market through appropriate regulatory certifications, thus contributing to improved diagnostic capabilities in healthcare.

Nasal is a technology-focused company that specializes in developing automated medical devices for the healthcare sector. It aims to enhance professional practices by providing tools that offer detailed insights into the structure and behavior of the nasal cavity. Through its innovative solutions, Nasal seeks to advance medical simulation technology, thereby assisting and training healthcare professionals. The company's efforts are geared towards improving the quality of care for patients and supporting the ongoing development of medical expertise.

Surgitate specializes in the manufacture of synthetic models aimed at enhancing the training experience for medical and veterinary students, as well as healthcare professionals such as nurses and obstetricians. The company produces a range of models, including synthetic skin, breast, and vascular components, designed to simulate realistic surgical procedures, including incision, dissection, and suturing. This hands-on practice enables users to develop their skills in a controlled environment. Founded by a materials engineer and a thoracic surgeon, Surgitate benefits from the expertise of its investors, Farplas, a leader in plastic automotive parts manufacturing, and Inovent, a pioneer in technology commercialization and seed funding in Turkey. Farplas provides essential support in process development and mass production, while Inovent facilitates connections with potential investors and assists in business and marketing strategies.

Scandion Oncology A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing treatments for chemotherapy resistance in cancer patients. Founded in 2017, the company is advancing its lead product, SCO-101, which is currently undergoing Phase II clinical trials for breast and colorectal cancers. Additionally, it is working on SCO-201, a product in late pre-clinical development aimed at treating solid tumors. Scandion Oncology collaborates with the University of Copenhagen to co-develop SCO-301, a candidate designed to reverse drug resistance, and has partnered with Per Norlén to investigate the combined anti-tumor effects of mitazalimab and SCO-101 in resistant tumor models. The company's mission is to enhance treatment outcomes and quality of life for cancer patients who experience chemotherapy resistance, addressing a significant challenge in oncology where nearly half of patients do not respond to chemotherapy.

OnDosis is a company focused on transforming medication delivery through its proprietary technology, which allows for flexible and individualized dosing of oral medicines formulated as micro units. The company aims to enhance disease management, support patient adherence, and improve convenience for individuals with conditions such as ADHD, pain management, and organ transplant immunosuppression. By offering improved dosing options, OnDosis seeks to address significant healthcare burdens and ultimately enhance patient outcomes. Founded in 2017 and headquartered in Gothenburg, Sweden, OnDosis emerged from research initiated at AstraZeneca and is supported by strategic partnerships in formulation, device development, regulatory affairs, and business development. The company's innovative dosage manager integrates digital technologies with conventional drug treatments, positioning it to make a meaningful impact in personalized medicine.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Brainmarc Ltd. is a company based in Yokne'am, Israel, with an additional location in Hoboken, New Jersey, that specializes in developing a digital platform for cognitive remediation. Founded in 2013, the company utilizes its proprietary Brain Engagement Index (BEI) technology to measure brain engagement and mental activity through electroencephalography (EEG) sensors integrated into headsets. Brainmarc's platform offers therapeutic products aimed at addressing cognitive and mental disorders, demonstrating significant effectiveness in treating cognitive impairments. This technology has been validated through numerous patient cases in clinical settings across the United States, Canada, the European Union, and Israel, providing a reliable solution for measuring attention levels during cognitive exercises.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Eden Microfluidics is a young innovative company founded in 2017. The company aims to provide advanced and certified materials, microfabrication and microfluidics solutions to both researchers and industrial partners. Eden Microfluidics is driven by a team of talented and passionate scientists, innovators and entrepreneurs, thriving to develop radical microfluidic solutions, for biomedical to environmental challenges. All together, they assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems. Eden Microfluidics is here to offer you access to the latest, up-to-date microfluidic science and technology.

CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

FGen GmbH, founded in 2011 in Basel, Switzerland, specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries. This innovative approach facilitates the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in the biotechnology, life sciences, and pharmaceutical sectors to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on creating optimized microbial strains for various biotechnological applications, utilizing proprietary screening technology alongside biological engineering tools. This enables clients to achieve efficient and cost-competitive production of chemicals and proteins.

Raylytic GmbH is a technology company based in Leipzig, Germany, specializing in automated medical image analysis and clinical data collection. The company's primary product, the UNITY platform, is a fully integrated software solution that streamlines the setup and execution of clinical trials by automating the analysis of medical images and the collection of clinical data. UNITY supports various tasks, including the management of case report forms (CRFs), patient-reported outcome measures (PROMs), and regulatory compliance for clinical trials and post-market surveillance. Raylytic's software employs proprietary algorithms for the precise evaluation of radiological images, enabling users to conduct independent qualitative analyses and ensure quality assurance across surgical procedures. Founded in 1999, Raylytic also offers services such as clinical documentation, data management, statistical analysis, and medical writing support, making it a comprehensive resource for evidence-based medicine and regulatory compliance in the medical field.

Brain Stimulation AB is a Swedish small and medium-sized enterprise established in 2011, focusing on the assessment and rehabilitation of patients recovering from strokes and traumatic brain injuries. The company utilizes advancements in brain plasticity research to offer innovative rehabilitation solutions, particularly for cognitive impairments and attention disabilities, such as Spatial Neglect. By addressing the global need for effective rehabilitation in conditions like stroke, dementia, traumatic brain injuries, and Parkinson's disease, Brain Stimulation employs a concept known as Enriched Rehabilitation. Their approach combines precision diagnostics with individualized care technology, facilitating effective neurological rehabilitation that can be accessed remotely. This method aims to create a motivating rehabilitation environment that leads to proven and lasting improvements in patients' cognitive and motor functions, ultimately enhancing their recovery process.

Respinova specializes in the development of non-invasive devices for the treatment of respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's primary product, the PulseHaler, leverages innovative technology that generates dynamic air pressure pulses. These pulses travel quickly through the airways, creating momentary dilating forces that help open collapsed airways and facilitate mucus clearance. By smoothing and spreading the mucus lining within the airways, the PulseHaler aids in airway clearance and reduces the likelihood of airway re-collapse, providing a significant improvement in treatment options for COPD patients.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

Double Bond Pharmaceutical is a pharmaceutical company focused on developing and commercializing innovative treatments for cancers, infections, autoimmune diseases, and other life-threatening conditions. The company aims to address unmet medical needs by providing more efficient and safer therapeutic options for patients. Through its first-in-class approaches, Double Bond Pharmaceutical seeks to improve patient outcomes and contribute significantly to the healthcare market.

Anima is a unique AI-based short-screening solution for early detection of children suffering from sexual abuse. The tool will screen and identify experience of sexual abuse at an early stage, thus prevent further abuse and providing treatment. This in turn will reduce future mental and physical negative consequences of the abuse.

CMS Dental provides products and treatment concepts for the modulation of biofilm and for preventing infectious conditions of the oral cavity. In their field of endodontics, they developed root-filling systems. Their oral cavity is associated with the development of systemic chronic diseases including cardiovascular disease, alzheimer's, oral, pancreatic cancer, and arthritis.

Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.

EpiGuard is a Norwegian company founded in 2015 by a group of doctors from Oslo University Hospital, alongside co-founders Inven2, Eker Group, and Hansen Protection. The company specializes in the development and manufacture of medical transportation systems designed to safely transfer patients with contagious diseases. EpiGuard's flagship product is a single-patient isolation and transport system that helps prevent the spread of infections to the environment and protects patients from contaminated surroundings. This innovation not only safeguards medical staff but also ensures that patients receive proper care during transport. With expertise spanning various medical fields, including intensive care and infectious diseases, EpiGuard aims to enhance safety and efficiency in patient transport.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of innovative hearing solutions tailored for individuals with varying degrees of hearing impairment. Originating as a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic Tübingen, Vibrosonic focuses on creating discreet hearing devices that integrate advanced microsystem technologies. Their unique approach involves the use of piezoelectric principles to design hearing contact lenses that can be directly placed on the eardrum. This technology transmits sound through vibrations rather than traditional speakers, enhancing the auditory experience while minimizing discomfort for users. Through its specialized equipment, Vibrosonic aims to improve the quality of life for those affected by hearing loss.

IDConference is focused on Conferences, initially targeting regulated conferences, which are attended by medical experts, law professionals, etc. Solution including ticketing, accreditation/badging, different options of tracking tools where specialty is UHF RFID tower for seamless tracking or passage control of conference attendees, mobile app, lead retrieval for exhibitors and marketing automation tool.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

Vetbiobank is a biotech company specializing in veterinary regenerative medicine. The company develops cell and tissue therapies aimed at enhancing animal health and care. In addition to its focus on veterinary applications, Vetbiobank also engages in human cellular and tissue therapies. It supplies veterinarians with clinical-grade cell and tissue products, thereby supporting medical and scientific needs within the veterinary field. Through its innovative approach, Vetbiobank aims to improve outcomes for animals by advancing regenerative medicine techniques.

BioSpeedia develops and manufactures a vitro diagnostics rapid test kits and ELISA kits for medical professionals.

EarWays Medical Ltd. is an innovative company focused on developing ear-care solutions aimed at improving the well-being of children and adults globally. The company specializes in a medical device designed for the effective removal of earwax, utilizing a patented technology that features a flexible, coated helical tip for easy navigation in the ear canal. This device is suitable for both clinicians and home users, facilitating the management and extraction of cerumen. Backed by a team of experts in bioengineering, medical devices, and ear health, EarWays Medical is well-positioned to address the medical demand for accessible and effective ear care, helping to prevent temporary hearing loss caused by earwax buildup.

Healthplus.ai specializes in a surgical patient risk management platform that leverages electronic health record data to enhance surgical care. By utilizing AI and machine learning algorithms, the platform integrates seamlessly with existing EHR workflows to predict potential complications following surgery. This proactive approach allows healthcare professionals to identify early warnings of post-surgery infections and other significant risks, thereby improving patient outcomes and reducing overall costs. Healthplus.ai's technology empowers clinical staff to deliver tailored support to patients, ultimately fostering a more effective and efficient surgical care environment.

SensoGenic, Inc. develops innovative diagnostic biosensors specifically designed to detect food allergens. Founded in 2016 and based in Ness Ziona, Israel, the company offers portable, handheld analyzers that connect to a mobile application, allowing users to identify allergens without physical contact. This technology provides critical information for individuals with food allergies, enabling them to dine out safely and avoid allergic reactions. SensoGenic emphasizes understanding user needs to enhance the functionality and usability of its products, positioning itself as a leader in allergen detection solutions.

ImmuneBiotech AB, founded in 2013 and based in Lund, Sweden, specializes in the research and development of innovative microbiome therapeutics. The company focuses on creating novel probiotics derived from lactic acid bacteria and synbiotic formulations that aim to influence gut microbiota and immune system responses. ImmuneBiotech's therapeutic products include combinations of probiotics, prebiotics, and proteins, specifically designed to address various inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. By leveraging its online platform, the company seeks to enable healthcare professionals to prevent and treat autoimmune and other chronic inflammatory conditions effectively.

Mimetis Biomaterials SL is a Spanish company founded in 2013, specializing in the design and manufacture of biomimetic bone graft substitutes for medical applications in dental, craniomaxillofacial, and orthopedic sectors. The company focuses on creating synthetic bone grafting solutions that mimic the properties of natural bone, thereby facilitating the colonization of grafts by bone cells and improving outcomes in complex cases. Mimetis offers a range of products, including biomaterial granules and patient-specific 3D-printed grafts, to address various bone defect filling needs. In addition to its product offerings, the company provides consulting, original equipment manufacturing, and co-development services to clinicians. Mimetis Biomaterials was previously known as Subtilis Biomaterials S.L. until its name change in January 2016 and is headquartered in Barcelona, Spain.

Stokhos B.V., based in Amsterdam, Netherlands, develops software aimed at optimizing the deployment of emergency vehicles, particularly ambulances. Initially conceived as a scientific mathematical project named REPRO, the company's flagship product, known as seconds, utilizes advanced algorithms to provide real-time coverage advice to emergency dispatch centers. By analyzing factors such as population density, historical incident data, and road networks, Stokhos's platform enables dispatchers to determine the optimal placement of ambulances, ensuring that they can respond swiftly to emergencies within required timeframes. The team at Stokhos is deeply committed to enhancing public safety and has a strong connection to the medical emergency sector, with all members holding valid first aid certifications.

MyCol d.o.o. is a women-owned start-up established in March 2017 by researchers specializing in materials science, chemical and graphic technology, and environmental science. The company was formed as part of a research initiative on chromogenic materials at the National Institute of Chemistry in Ljubljana, Slovenia. MyCol focuses on developing innovative solutions for visual temperature control through smart labels made from temperature-sensitive chromogenic materials. These labels change color when a specific temperature threshold is exceeded, providing a clear visual signal without the need for electric power or IT infrastructure. The products can be customized in various designs and are suitable for both reversible and irreversible temperature monitoring. MyCol aims to assist clients by offering unique temperature indicators that enhance safety and control in various applications.

Nateo Healthcare, founded in 2016 and based in Toulouse, France, specializes in designing, developing, and manufacturing medical devices for the fields of gynecology and obstetrics. The company focuses on creating innovative connected medical devices and software that enable healthcare professionals to monitor the health of expectant mothers and their unborn babies. Among its key products is a belt equipped with ultrasound probes that can assess fetal positions, measure the mother's heart rate, and monitor uterine contractions. Additionally, Nateo Healthcare is working on a new generation of mobile and connected fetal heart rate monitors, which facilitate both hospital and home fetal telemonitoring, allowing for enhanced patient self-monitoring and tailored healthcare interventions.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Toleranzia AB is a Swedish biotechnology company focused on developing innovative drugs that leverage the immune system to treat autoimmune orphan diseases. Unlike conventional treatments that primarily alleviate symptoms, Toleranzia's approach aims to address the root causes of these conditions, potentially offering cures or significant improvements in patient health. One of its key drug candidates, TOL2, is specifically designed for myasthenia gravis, an autoimmune neuromuscular disorder classified as an orphan disease. Through its targeted therapies, Toleranzia seeks to make a meaningful impact on the lives of patients suffering from these challenging conditions.

Allergy Data Laboratories continues to manage and support the Allergome project.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

300K is a biotechnology start-up composed of a multidisciplinary team with expertise in developing and commercializing innovative life sciences products and services. The company specializes in creating solutions for the storage and shipment of bio-specimens at room temperature. Its stabilization technology enhances the preservation of biological samples, ensuring a secure process while optimizing storage space in life science facilities. By enabling laboratories to stabilize biospecimens at room temperature, 300K aims to minimize sample loss and improve the overall efficiency of biosample management.

InSCREENeX GmbH is a biotechnology company based in Braunschweig, Germany, founded by Dr. Roland Schucht as a spin-off from the Helmholtz Centre for Infection Research. The company specializes in cellular screening technologies aimed at accelerating the drug discovery process for pharmaceutical and drug development firms. By employing advanced genetic manipulation techniques, InSCREENeX develops innovative and user-friendly mammalian cell systems that serve as effective decision-making tools throughout the drug development pipeline. The company's offerings include the generation of specialized cell lines for primary screening and the design of physiologically relevant cell types for secondary screening and profiling, ultimately reducing the time and costs associated with biopharmaceutical drug discovery and validation.

Scandinavian ChemoTech AB is a clinical development company headquartered in Lund, Sweden. It specializes in cancer care and pain management solutions, primarily through its innovative product, IQWave. This electroporation device uses short electric pulses in conjunction with localized or intravenous chemotherapy to treat various cancers, including head and neck squamous cell carcinoma, malignant melanoma, and breast adenocarcinoma, among others. The company's founders bring extensive experience in surgical oncology and clinical research, driving its commitment to advancing cancer treatment through genuine research and clinical trials. ChemoTech markets its products via distribution channels and a network of opinion leaders across regions such as South East Asia, India, and the Philippines. Established in 2013, the company continues to focus on developing effective therapies for cancer patients.

CardiacSense Ltd. is an Israeli company founded in 2012, specializing in the development of medical wearable devices aimed at monitoring heart arrhythmias and other critical health metrics. The company offers FDA and CE certified medical watches and wristbands that provide continuous, long-term, non-invasive monitoring of vital signs, including heart rate, respiratory rate, core temperature, oxygen saturation, and blood pressure. Utilizing advanced photoplethysmography (PPG) technology, CardiacSense's devices enable real-time diagnostics for various medical conditions, including atrial fibrillation, hypertension, chronic obstructive pulmonary disease (COPD), heart failure, sleep apnea, and infections such as COVID-19. By focusing on affordability and comfort, CardiacSense aims to enhance patient care and preventative measures within the healthcare industry.

Domalys SAS, established in 1990 and based in Vienne, France, specializes in providing innovative solutions and customized products aimed at enhancing the lives of elderly individuals and their caregivers. The company offers a range of products, including the Aladin lamp and telecare assistance, as well as tracking software and specialized tables designed for use in nursing homes. Domalys focuses on preventing falls and detecting early warning signs of health issues through intelligent lighting and technology that is co-designed with care staff. By addressing the specific needs of dependent elderly individuals, Domalys aims to improve their daily lives and the experiences of those who care for them.

7scientists current academic research findings into practical solutions.

Dytective is the scientifically validated reference tool for detection and improvement of skills related to dyslexia. Dytective combines two scientifically validated tools developed by Change Dyslexia. In only 15 minutes, through a series of tests, according to your age and abilities, Dytective Test detects if you are at risk of having dyslexia. With DytectiveU you will improve your reading and writing skills while having fun playing.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.

Minnemera is a company based in Stockholm, Sweden, that specializes in developing digital cognitive screening tools. Founded in 2017, the company focuses on creating neurocognitive tests that automatically compare individual results with normative data and personal baseline values to identify abnormalities. This innovative approach aims to enhance the assessment of cognitive function and support healthcare professionals in diagnosing and monitoring cognitive health.

Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.

VisionHealth GmbH is a healthcare technology company based in Munich, Germany, founded in 2017. It specializes in creating software solutions for patients with various respiratory diseases, particularly those reliant on inhalers for conditions such as asthma and COPD. Its primary product, Kata, is a digital healthcare assistant that utilizes artificial intelligence and machine learning to improve inhalation therapy. The application facilitates effective inhaler use by providing training and support, helping patients avoid shortness of breath and reduce the need for hospital visits. By enhancing the management of chronic lung conditions, VisionHealth aims to lower therapy costs and improve the overall quality of life for patients.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

ODI Medical specializes in developing innovative technology for the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's medical device streamlines the collection of microvascular data and has diverse clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, and early detection of evolving sepsis. Additionally, the technology is useful for monitoring chronic wounds and conducting mass screenings for conditions such as Ebola, bird flu, and epidemic meningitis. By employing non-invasive techniques, ODI Medical enables healthcare professionals to enhance patient therapy through improved assessment of microcirculation.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Pre Diagnostics is a Norwegian diagnostic company specializing in the development of innovative in-vitro diagnostic (IVD) products aimed at the early detection of diseases, particularly neurodegenerative conditions like Alzheimer’s disease. The company leverages a proprietary approach based on the premise that specific diseases trigger unique systemic responses in macrophages, which can be measured through blood samples. By focusing on intracellular measurements of disease-specific biomarkers within blood cells, Pre Diagnostics aims to provide healthcare professionals with actionable insights for early diagnosis. Their commitment to creating patient-friendly solutions positions them as a potential leader in the field of early Alzheimer’s detection, utilizing established technologies to develop their biomarker products.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

PreOmics GmbH, founded in 2016 and based in Planegg, Germany, specializes in mass spectrometry (MS)-based proteomics. The company develops innovative tools, including the iST Kit, designed for efficient sample preparation and peptide pre-fractionation, which allows researchers to process peptide mixtures in just one hour. PreOmics focuses on providing solutions for the identification of protein interaction partners, large-scale protein discovery, and quantification of proteins, as well as the analysis of post-translational modifications. As a spin-off from the Max-Planck Institute of Biochemistry, the company aims to enhance protein analysis for researchers worldwide by offering high-quality technologies that streamline and improve research outcomes.

Espansione Group is a medical technology company specializing in the development and distribution of innovative, non-invasive devices for ophthalmology. Their product portfolio includes proprietary photobiomodulation devices, light therapy systems using red, blue, and ultraviolet light, and diagnostic tools for eye screening. These solutions are designed to enhance patient outcomes by leveraging advanced, science-driven therapies, primarily serving the ophthalmology field.

Chemicare is a biotechnology company established in December 2016, focused on the discovery and development of orphan drugs for patients with calcium-related genetic diseases. The company aims to improve the quality of life for individuals suffering from conditions such as Tubular Aggregate Myopathy, York Platelet Syndrome, and Stormorken Syndrome. Chemicare is dedicated to creating therapies that address the abnormal intracellular calcium levels characteristic of these rare diseases, enabling healthcare professionals to provide effective treatment options for affected patients.

Amypore is focused on developing innovative therapies for Alzheimer's and Parkinson's diseases through its lead product, AmyP53. This chimeric peptide is created using an advanced artificial intelligence strategy applied to molecular neuroscience. AmyP53 targets a common mechanism in both neurodegenerative diseases by blocking the formation of neurotoxic structures, specifically oligomers of amyloid proteins, which are implicated in disease progression. As the first representative of a new therapeutic class, AmyP53 offers a unique approach to treatment, aiming to provide patients with effective solutions for conditions that currently lack adequate therapies.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.

Segmentum Imaging is a brand new app allowing you to count samples more quickly than traditional methods have previously allowed, whilst releasing you from the confines of the lab. Do your work conveniently, increasing your output and decreasing your time spent on repetitive actions. The adoption of digital pathology has been increasing dramatically. It is being used for more convenient diagnosis, easier sharing of images between consultants, large-scale collection for research purposes and in the creation of online virtual archives, critical in teaching and multi-centre research. Whilst the tools for researchers to utilise digital images have become very advanced, they are often very expensive and are commonly based in individual laboratories. This can easily result in considerable bottlenecks in use and limitations of access often lead to these facilities being simultaneously very costly but under-utilised.

ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.

Vetherapy Corp., established in 2015 and headquartered in San Francisco, specializes in veterinary regenerative medicine and tissue engineering. The company produces stem cell therapy products for cats, dogs, and horses, focusing on accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy's offerings include stem cell and platelet-rich plasma (PRP) banking services, ensuring veterinarians have access to safe and efficient products for various animal health conditions.

Cambridge Mask Co specializes in the manufacture and distribution of high-performance consumer pollution masks that utilize advanced filter technology originally developed for military applications in chemical, nuclear, and biological warfare. Their masks are designed to filter nearly 100% of viruses, bacteria, gases, and particulate matter, providing effective protection against air pollution. Available in various sizes and patterns to accommodate families, these masks have gained recognition and are supplied to notable clients, including the United Nations and British Airways. The company's commitment to health and safety is reflected in its use of military-grade filtration technology, which incorporates activated carbon cloth to ensure optimal protection for users.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.

Diabeloop is a medical device company based in Grenoble, France, focused on innovating diabetes treatment through advanced technology. Founded in 2015, the company specializes in developing an AI-based closed-loop system that automates insulin delivery for individuals with type 1 diabetes. This system includes a blood sugar monitoring device that combines a glucose sensor, an insulin pump, and a smartphone application featuring an embedded algorithm. By continuously measuring glucose levels and delivering the appropriate insulin dosage, Diabeloop aims to reduce the mental burden on patients, allowing them to manage their condition more effectively and live their lives with greater ease.

Deneb Medical is a start-up focused on creating a robotic platform intended for various surgical applications, including neurosurgery, cranio-maxillofacial surgery, head and neck surgery, urology, and general surgery. The company's technology centers around a laser-based robotic surgery system that assists surgeons, particularly in spine surgery, by utilizing optical and photonic techniques for tissue ablation. This innovative system enhances surgical precision and efficiency through features such as three-dimensional visualization and augmented reality guidance, ultimately aiming to facilitate minimally invasive procedures and improve patient outcomes.

PlumeSTARS is a specialized pharmaceutical company focused on drug delivery systems for the treatment of respiratory diseases. The company develops antibiotics specifically designed to address lung infections in patients with Cystic Fibrosis. By discovering novel orphan medicines and utilizing advanced technologies for various active pharmaceutical ingredients (APIs), PlumeSTARS aims to create innovative inhalation therapies that improve patient outcomes. Their commitment to developing effective treatments positions them as a significant player in the field of respiratory health.

CMI NOV is a healthcare company based in Monistrol sur Loire, France, specializing in the design, development, and manufacturing of medical devices for surgical applications. Founded in 2013, the company focuses on various medical fields, including cardiology, visceral surgery, gynecology, urology, and bariatrics. Notably, CMI NOV offers solutions for mitral valve repair, enhancing surgical procedures during open heart surgeries. Through its innovative products, the company aims to improve patient outcomes and support healthcare professionals in delivering high-quality surgical care.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art mass spectrometry based methodologies.

Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

Metys Pharmaceuticals is focused on developing MP-101, a small molecule drug designed to prevent and treat chemotherapy-induced peripheral neuropathy, a significant side effect of various cancer treatments. MP-101 acts as an orally-active modulator of glutamate signaling in the brain and spine, a mechanism that has been sought after for central nervous system drug development. The drug is a patent-pending non-racemic mixture of the enantiomers of dimiracetam, specifically formulated to enhance potency compared to traditional racemic mixtures. Metys Pharmaceuticals has secured exclusive global rights to racemic dimiracetam from Neurotune AG and aims to leverage existing pharmacological, toxicological, and clinical data to support future clinical trials for MP-101. Through its innovative approach, Metys Pharmaceuticals aims to provide effective treatments for neuropathic pain and improve patient outcomes in cancer care.

E-Motion Medical Ltd was founded in 2011 by a pioneering multidisciplinary team with extensive experience in medicine, science, management and business. The E-Motion System™ delivers unique patterns of stimulation to the esophagus, thereby generating contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract. The stimulation is applied to the esophagus using their proprietary E-Motion Tube™, which can also double as a feeding tube, and is easily placed in the same manner.

Virtual Bodyworks is a company committed to improving lives by harnessing the power of scientifically-proven breakthrough technology. Their company specialises in immersive virtual reality focused on medical and psychological rehabilitation. Founded by scientists world renowned for their work in VR, we offer products that integrate a unique combination of computer science engineering, neuroscience and psychology.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Clover Bioanalytical is a bioinformatics company that specializes in data processing for bioanalytical chemistry and clinical diagnostics applications, particularly utilizing mass spectrometry. Founded by a team of Ph.D. graduates with expertise in both business and research, the company focuses on developing advanced software and statistical analysis tools for the biomedical field. Clover’s capabilities extend beyond mass spectrometry to include medical image processing and both univariate and multivariate statistical analysis, addressing the challenges posed by Big Data. The company emphasizes a customer-oriented approach, aligning its solutions with the specific goals and scalability needs of its clients. By leveraging artificial intelligence, Clover aims to enhance the rapid identification of microorganisms, positioning itself as a key partner for hospitals, research institutions, and biotechnology companies in tackling significant scientific questions.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Bambi Medical is a MedTech company founded in November 2015 by Sidarto and Fabio Bambang Oetomo, aiming to alleviate pain and stress in pre-term infants while enhancing parent-child bonding. The company specializes in the design, development, and manufacturing of innovative products for Neonatal Intensive Care Units (NICUs) in hospitals. One of its key offerings is a wireless health monitoring device that tracks critical health metrics such as breathing, heart rate, temperature, and electrocardiogram (ECG) without the discomfort associated with traditional adhesive electrodes. This device facilitates maximum skin-to-skin contact between infants and their parents, allowing for effective monitoring of the baby's health while minimizing pain and skin irritation.

Biocompatibility Innovation (BCI), established in 2014 in Padua, Italy, specializes in biotechnologies for biomedical applications. The company develops and manufactures highly biocompatible implantable prostheses, both biological and polymeric, using its proprietary FACTA® and PROTEGO technologies. These innovations extend the lifespan of bioprostheses and enhance the biocompatibility of implantable medical devices. BCI also provides third-party testing services and develops new proprietary treatments. Led by experienced researchers and managers in biotech and biomedicine, BCI aims to improve clinical management, patient quality of life, and lower healthcare costs.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Lab-on-Fiber GmbH, based in Halle, Germany, specializes in the development and production of advanced medical laser probes and systems aimed at enhancing minimally invasive surgical procedures. The company offers a range of fiber delivery systems, including surgical and urology fiber probes. By providing optimized radiation profiles and real-time temperature monitoring at the probe surface, Lab-on-Fiber's technology helps surgeons reduce operating times, improve treatment outcomes, and enhance patient safety. Their innovative solutions are designed to streamline laser surgery while minimizing potential complications, positioning Lab-on-Fiber as a key player in the medical technology sector.

DermoSafe is a Swiss company based in Cheseaux, founded in November 2012 by Philippe Held. The company specializes in innovative medical devices designed for the early detection and management of melanoma. Its primary product captures high-definition dermoscopic images of moles and pigmented lesions, allowing general practitioners to enter patient data and refer images to dermatology specialists via a secure web application. This platform facilitates the analysis of images, enabling specialists to provide electronic reports that assist in the early identification of melanoma and the management of treatment. DermoSafe's approach enhances collaboration between primary care practitioners, patients, and specialists, ultimately aiming to improve outcomes in melanoma care.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.